Home » View latest Tenofovir Alafenamide Tenders from India

View latest Tenofovir Alafenamide Tenders from India

TendersOnTime provides latest updates on Indian Tenofovir Alafenamide Tenders from various state and central government tendering authorities. The information on Tenofovir Alafenamide online tenders and turnkey projects from India is collected from various sources viz: e procurement tenders list, newspapers and tender bulletin etc.

Country: India

Tenofovir Alafenamide 25 Mg Tablet

TOT Ref No.: 100026206

Deadline: 30 Apr 2024

Country: India

Tenofovir Alafenamide 25Mg Tab

TOT Ref No.: 100368279

Deadline: 03 May 2024

Country: India

Tab Tenofovir Alafenamide 25 Mg, Qty: 720 No, (BOQ Item #119)

TOT Ref No.: 99835328

Deadline: 30 Apr 2024

Country: India

Tab. Tenofovir Alafenamide 25Mg (30 Tab/Phial) Specn: 30 Tab/Phial

TOT Ref No.: 99953075

Deadline: 29 Apr 2024

Country: India

Tab Tenofovir 300Mg, Qty: 600 No, (BOQ Item #118)

TOT Ref No.: 99835327

Deadline: 30 Apr 2024

Country: India

Tab. Tenofovir 300Mg (Item No. 2278 of Ami 2024-25)

TOT Ref No.: 100162997

Deadline: 29 Apr 2024

Country: India

Supply Of Tenofovir Tablets 300 mg tab Qty:-3 box At Rishikesh

TOT Ref No.: 99581530

Deadline: 29 Apr 2024

Country: India

Tab Dolutegavirand Lamivudine and Tenofovir, Qty: 360 No, (BOQ Item #57)

TOT Ref No.: 100311354

Deadline: 13 May 2024

Country: India

Emtricinoine 200 Mg Pulse Tenofovir 300Mg Tab, Qty: 270 No, (BOQ Item #81)

TOT Ref No.: 100062991

Deadline: 07 May 2024

Country: India

Tab Tenofovir 300 Mg and Lamivudine 300 Mg and Dulatogravir, Qty: 360 No, (BOQ Item #12)

TOT Ref No.: 100064478

Deadline: 07 May 2024

Country: {{rowDetails.Country_Name}}

TOT Ref No.: {{rowDetails.ID}}

Deadline: {{rowDetails.Bid_Deadline_1}}

Deadline: {{rowDetails.Bid_Deadline_1}}

No data Found!! Please search again

Browse Tenders

Browse Tenders from below Sections

Call Action

Get A Callback Within 24 Hours

Fill form below to get callback from Tender Experts.

Click button to send your details.